Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units

• US 5,654,168 A
• Filed: 07/15/1994
• Issued: 08/05/1997
• Est. Priority Date: 07/01/1994
• Status: Expired due to Term

• Current Assignee: Tet Systems Holding GmbH & Company Kg
• Original Assignee: BASF AG (BASF SE), Knoll AG (BASF SE)
• Inventors: Gossen, Manfred, Bujard, Hermann
• Primary Examiner(s): Elliott, George C.
• Assistant Examiner(s): Brusca, John S.
• Application Number:
  US08/275,876
• Time in Patent Office: 1,117 Days
• Field of Search: 435/69.1, 435/172.3, 435/320.1, 536/23.7, 536/24.1
• US Class Current: 435/69.1
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2217/20 Animal model comprising regulated expression system
• CPC Class Codes: A01K 2267/01 Animal expressing industrially exogenous proteins
• CPC Class Codes: A01K 2267/03 Animal model, e.g. for test or diseases
• CPC Class Codes: C07K 14/245 Escherichia (G)
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/09 containing a nuclear localisation signal
• CPC Class Codes: C07K 2319/61 containing an enzyme fusion for detection (lacZ, luciferase)
• CPC Class Codes: C07K 2319/71 containing domain for transcriptional activaation, e.g. VP16
• CPC Class Codes: C07K 2319/80 containing a DNA binding domain, e.g. Lacl or Tet-repressor
• CPC Class Codes: C12N 15/63 Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• CPC Class Codes: C12N 15/635 Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
• CPC Class Codes: C12N 15/67 General methods for enhancing the expression
• CPC Class Codes: C12N 15/85 for animal cells
• CPC Class Codes: C12N 15/8509 for producing genetically modified animals, e.g. transgenic
• CPC Class Codes: C12N 2830/003 tet inducible
• CPC Class Codes: C12N 2830/006 tet repressible

Abstract

Nucleic acid molecules and proteins useful for regulating the expression of genes in eukaryotic cells and organisms in an inducible manner are disclosed. In the regulatory system of the invention, transcription of a tet operator-linked nucleotide sequence is stimulated by a transcriptional activator fusion protein composed of two polypeptides, a first polypeptide which binds to tet operator sequences in the presence of tetracycline or a tetracycline analogue and a second polypeptide which directly or indirectly activates transcription in eukaryotic cells. In one embodiment, the fusion protein comprises a mutated Tet repressor operatively linked to a transcriptional activation polypeptide, such as a portion of herpes simplex virus virion protein 16. In the absence of an inducing agent (tetracycline or a tetracycline analogue), transcription of the tet operator-linked nucleotide sequence remains uninduced. In the presence of the inducing agent, transcription of the tet operator-linked nucleotide sequence is stimulated by the transactivator fusion protein of the invention. Novel transcription units which allow for coordinate or independent tetracycline-regulated expression of two or more nucleotide sequences by the transactivator fusion protein of the invention are also disclosed. Kits including the components of the regulatory system of the invention are also encompassed by the invention.

Claims

1. An isolated nucleic acid encoding a fusion protein which activates transcription, the fusion protein comprising a first polypeptide which binds to a tet operator sequence in the presence of tetracycline or a tetracycline analogue operatively linked to a second polypeptide which activates transcription in eukaryotic cells.

2. The nucleic acid of claim 1, wherein the first polypeptide is a mutated Tet repressor.

3. The nucleic acid of claim 2, wherein the mutated Tet repressor has at least one amino acid substitution compared to a wild-type Tet repressor.

4. The nucleic acid of claim 2, wherein the mutated Tet repressor has at least one amino acid addition or deletion compared to a wild-type Tet repressor.

5. The nucleic acid of claim 3, wherein the mutated Tet repressor is a mutated Tn10-derived Tet repressor having an amino acid substitution at at least one amino acid position selected from the group consisting of position 71, position 95, position 101 and position 102.

6. The nucleic acid of claim 5, wherein the mutated Tn10-derived Tet repressor comprises an amino acid sequence shown in positions 1 to 207 of SEQ ID NO:

2.

7. The nucleic acid of claim 1, wherein the second polypeptide comprises a transcription activation domain of herpes simplex virion protein 16.

8. The nucleic acid of claim 7, wherein the transcription activation domain comprises a C-terminal amino acid region of herpes simplex virus virion protein 16 comprising an amino acid sequence shown in positions 208 to 335 of SEQ ID NO:

2.

9. The nucleic acid of claim 7, wherein the transcription activation domain comprises at least one copy of a C-terminal region of herpes simplex virus virion protein 16 comprising an amino acid sequence shown in SEQ ID NO:

4.

10. The nucleic acid of claim 1, wherein the second polypeptide comprises a transcription activation domain selected from the group consisting of:

an acidic transcription activation domain, a proline-rich transcription activation domain, a serine/threonine-rich transcription activation domain and a glutamine-rich transcription activation domain.

11. The nucleic acid molecule of claim 1, wherein the fusion protein further comprises an operatively linked third polypeptide which promotes transport of the fusion protein to a cell nucleus.

12. A recombinant vector comprising the nucleic acid molecule of claim 1 in a form suitable for expression of the fusion protein in a host cell.

13. The recombinant vector of claim 12, wherein expression of the fusion protein is regulated by at least one tissue-specific regulatory element.

14. The recombinant vector of claim 12 wherein expression of the fusion protein is regulated by at least one tet operator sequence.

15. A host cell comprising the recombinant vector of claim 12.

16. The host cell of claim 15, futher comprising a nucleotide sequence to be transcribed operatively linked to at least one tet operator sequence.

17. The host cell of claim 16, wherein the nucleotide sequence to be transcribed is an exogenous nucleotide sequence introduced into the host cell.

18. The host cell of claim 16, wherein the nucleotide sequence to be transcribed is an endogenous nucleotide sequence to which at least one tet operator sequence has been operatively linked.

19. The host cell of claim 16, which is a mammalian cell.

20. The host cell of claim 17, which is a human cell.

21. The host cell of claim 16, which is a yeast, insect or fungal cell.

22. A method for stimulating transcription of the nucleotide sequence operatively linked to the at least one tet operator sequence in the host cell of claim 16 comprising contacting the host cell with tetracycline or a tetracycline analogue.

23. The method of claim 22, wherein the tetracycline analogue is anhydrotetracycline or doxycycline.

24. A process for producing and isolating a protein comprising:

a) growing the host cell of claim 16 at production scale in a culture medium in the presence of tetracycline or a tetracycline analogue to stimulate transcription of the nucleotides sequence operatively linked to the at least one tet operator sequence; and

b) isolating a protein encoded by the nucleotide sequence from harvested host cells or from the culture medium.

25. The production process of claim 24, wherein the host cell is a mammalian, yeast or fungal cell.

26. A kit comprising a carrier means having in close confinement therein at least two container means comprising:

a) a first container means containing a first nucleic acid encoding a fusion protein which activates transcription, the fusion protein comprising a polypeptide which binds to a first class of tet operator sequence in the presence of tetracycline or a tetracycline analogue operatively linked to a polypeptide which activates transcription in enkaryotic cells; and

b) a second container means containing a second nucleic acid comprising a first cloning site for introduction of a first nucleotide sequence to be transcribed operatively linked to at least one tet operator sequence of a first class type.

27. The kit of claim 26, wherein the first container means contains a enkaryotic cell line into which the first nucleic acid has been stably introduced.

28. The kit of claim 26, further comprising a third container means containing a tetracycline or a tetracycline analogue.

29. The kit of claim 28, wherein the tetracycline analogue is anhydrotetracycline or doxycycline.

30. The kit of claim 26, wherein the second nucleic acid further comprises a second cloning site for introduction of a second nucleotide sequence of interest located at an opposite end of the at least one tet operator sequence relative to the first cloning site, wherein transcription of a first and second nucleotide sequence introduced into the second nucleic acid proceeds in opposite directions relative to the at least one tet operator sequence.

31. The kit of claim 26, further comprising:

c) a third container means containing a third nucleic acid encoding a second fusion protein which activates transcription, the second fusion protein comprising a polypeptide which binds to a tet operator sequence of a second class type in the absence of tetracycline or a tetracycline analogue operatively linked to a polypeptide which activates transcription in eukaryotic cells; and

d) a fourth container means containing a fourth nucleic acid comprising a second cloning site for introduction of a second nucleotide sequence of interest operatively linked to at least one tet operator sequence of a second class type.

32. The kit of claim 31, further comprising a fifth container means containing a tetracycline or a tetracycline analogue.

33. The kit of claim 32, wherein the tetracycline analogue is anhydrotetracycline or doxycycline.